Category:

New York court…reaffirmed an injunction against Actavis that requires the pharmaceutical company to continue promoting and selling Namenda, an old medication… Actavis wanted to downscale its support of the drug.. The court's decision is a landmark ruling because it will force a company to manufacture, market, and distribute a product it no longer wishes to support. We need a better system that has less potential to dampen competition and innovation.

California pharmacist Afrouz Nikmanesh recently filed a class-action lawsuit against Walmart, alleging the retail giant cheated her and her colleagues out of work breaks and overtime pay.

Consumers across the nation are starting to file lawsuits against insurers who deny them access to expensive new hepatitis C treatments. Two lawsuits allege Anthem Blue Cross refused to pay for individual women’s Harvoni treatments because it was not deemed "medically necessary."

Can the US Drug Enforcement Administration use an "administrative subpoena" to obtain information from a database of transactions maintained by a state government of prescriptions of controlled substances, or is the expectation of privacy of such information so significant that the DEA’s motives for wanting such information need to be more thoroughly vetted before being able to access the data?

..he pressed play on his way home, he was shocked out of his anesthesia-induced stupor: He found that he had recorded the entire examination and that the surgical team had mocked and insulted him as soon as he drifted off to sleep...instructing an assistant to lie to him, and then placed a false diagnosis on his chart.

A California lawsuit accuses two surgeons and four hospitals in Las Vegas of participating in a massive health care fraud scheme that involved implanting counterfeit spinal hardware into unsuspecting patients.

China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents…..Gilead has drawn fire for the cost of its top-selling drug Sovaldi, priced at $1,000 per pill…..its patents have been challenged in the U.S., India and Europe.

…dismissing most of Nikmanesh’s claims,… ruled that the lawsuit “lacked sufficient factual allegations” to support claims that Walmart cheated pharmacists out of work breaks, overtime pay, and did not compensate pharmacists for time spent studying for and completing immunization-training programs…the lawsuit gained new life recently when Guilford denied Walmart’s motion to dismiss it, ruling..

The California Supreme Court has ruled pay-to-delay agreements among pharmaceutical companies violate state antitrust laws. The case came about after a brand name pharmaceutical company, Bayer, maker of the blockbuster antibiotic Cipro, paid Barr, a maker of generic drugs, to delay sales of a biosimilar generic drug, thus forestalling competition against Bayer.

A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.